Milton Essex forms biotech group

Milton Essex is creating a new medical-biotechnology capital group by integrating Sanford Biotech, following shareholder approval at an Extraordinary General Meeting on the Warsaw Stock Exchange. The move establishes the first med-biotech group on NewConnect and includes an investment issue of up to €5 million through Series N shares.

The partnership gives Milton Essex corporate control of Sanford Biotech and its…